Dr. Mel Spigelman

Dr. Mel Spigelman

Venture Partner

Biography

Mel Spigelman joined the Wellington Partners Life Science team as a Venture Partner in 2005. He advises on clinical development, regulatory affairs and strategic decisions. Since 2003, Mel has been serving as R&D Director of the New York-based Global Alliance for TB Drug Development. This not-for-profit organization is dedicated to the rising challenge of innovative treatment for TB. He has also been involved in venture capital since 2002, as an independent advisor to U.S. and European VC firms, including Wellington. From 1989 to 2001, Mel held various key positions at BASF Pharma, culminating in Vice President Global Clinical Centers. Here, he established a track record in global development and registration of drugs in the indications of cardiovascular medicine, endocrinology, oncology, and immunology. Mel holds a B.A. in engineering and an MD from the Mount Sinai School of Medicine, New York, where he also worked as Assistant Professor for several years.